MedTrace Logo

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

NCT04871204 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-10-31

No results posted yet for this study

Summary

The aim of the study is to clarify whether octreotide therapy can reduce undesired postoperative weight loss, increase health-related quality of life and improve the appetite after surgery for esophageal or gastric cancer.

Conditions

Interventions

DRUG

Octreotide Injection

10 mg Sandostatin LAR intramuscular injection

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • Fredrik Klevebro

    lead OTHER

Principal Investigators

  • Fredrik Klevebro, MD, PhD · Center for Upper Gastrointestinal Cancer, Theme Cancer, Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2024-02-21
Completion
2024-02-21

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871204 on ClinicalTrials.gov